Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.66 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.66 |
| ▸ | HCAR2 | Q8TDS4 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | DDO | Q99489 | 1/20 | 0.52 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.50 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.49 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30067639 | 1.00 | ATM (0.67) | ATMCYP2C9CYP2C19HCAR2KDM4E | |
| Benzene SCHEMBL28318053 | 0.98 | ATM (0.65) | ATMCYP2C9CYP2C19HCAR2KDM4E | |
| Hydrochloric Acid SCHEMBL8098340 | 0.98 | ATM (0.65) | ATMCYP2C9CYP2C19HCAR2KDM4E | |
| SCHEMBL4099107 | 0.98 | ATM (0.65) | ATMCYP2C9CYP2C19HCAR2KDM4E | |
| Cyclopropane SCHEMBL11659703 | 0.94 | ATM (0.61) | ATMCYP2C9CYP2C19HCAR2KDM4E | |
| SCHEMBL56951 | 0.92 | ATM (0.77) | ATMCYP2C9CYP2C19KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL2298745 | 0.90 | ATM (0.74) | ATMCYP2C9CYP2C19KDM4EALDH1A1 | |
| SCHEMBL431955 | 0.84 | ATM (0.67) | ATMCYP2C9CYP2C19KDM4EALDH1A1 | |
| SCHEMBL22832279 | 0.83 | CYP2C9 (0.65) | ATMCYP2C9CYP2C19HCAR2KDM4E | |
| SCHEMBL51830 | 0.82 | HCAR2 (0.70) | CYP2C9CYP2C19HCAR2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 140 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117344369-A | Method for preparing low-humidity water-absorbing aluminum-based MOF material monocrystal based on carboxylate hydrolysis | 浙江大学 | 2024-01-05 | — | — | CN | claimed |
| CN-115594843-A | Synthesis method of electron mediator, biosensor and preparation method of biosensor | 可孚医疗科技股份有限公司（CN） | 2023-01-13 | — | — | CN | claimed |
| CN-1418627-A | Nitrophendipine oral disintegrant for treating angina pectoris, and its prepn. method | WANG DENGZHI (CN) | 2003-05-21 | — | — | CN | claimed |
| EP-0330470-A2 | 1,4-Dihydropyridine derivatives useful against tumour cells | AJINOMOTO CO., INC. (JP) | 1989-08-30 | — | — | EP | claimed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12304907-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12264154-B2 | Compounds and methods of use | TANGO THERAPEUTICS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| CN-119410358-A | Organic room temperature phosphorescent material and preparation method thereof | 华东理工大学 | 2025-02-11 | — | — | CN | disclosed |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-26 | — | — | US | disclosed |
| EP-4192812-B1 | INHIBITORS OF TRANSGLUTAMINASES | ZEDIRA GMBH (DE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-08-22 | — | — | US | disclosed |
| WO-2024153208-A9 | MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2024-08-22 | — | — | WO | disclosed |
| EP-0672059-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995018111-A1 | COMPOUNDS CONTAINING BASIC AND ACIDIC TERMINI USEFUL AS FIBRINOGEN RECEPTOR ANTAGONISTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-07-06 | — | — | WO | disclosed |
| WO-1994011398-A1 | CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0267794-B1 | PROCESS FOR PREPARING POLYOLEFINS | Nippon Petrochemicals Co., Ltd. (JP) | 1993-05-05 | — | — | EP | disclosed |
| EP-0353238-A1 | NEW INTERMEDIATE PRODUCTS AND PROCESS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1990-02-07 | — | — | EP | disclosed |
| WO-1988007524-A1 | NEW INTERMEDIATE PRODUCTS AND PROCESS | BYK GULDEN LOMBERG CHEMISCHE FABRIK GMBH (DE) | 1988-10-06 | — | — | WO | disclosed |
| EP-0267794-A2 | Process for preparing polyolefins | Nippon Petrochemicals Co., Ltd. (JP) | 1988-05-18 | — | — | EP | disclosed |
| US-4525555-A | TITANIUM COMPOUND SUPPORTED ON SOLID REACTION PRODUCT OF MAGNESIUM HALIDE, SILOXANES, ORGANIC COMPOUNDS | NIPPON OIL COMPANY, LIMITED (JP) | 1985-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279219-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ATM 3957/4885CYP2C9 10/4885CYP2C19 20/4885 |
| US-12264154-B2 | Compounds and methods of use | F12, C1R, ABCG2 | ATM 3957/4885CYP2C9 10/4885CYP2C19 20/4885 |
| US-20240317708-A1 | INHIBITORS OF TRANSGLUTAMINASES | TGM2, TGM3, TGM1 | ATM 4295/4885CYP2C9 349/4885CYP2C19 369/4885 |
| US-12304907-B2 | Compounds and methods of use | F12, C1R, ABCG2 | ATM 3957/4885CYP2C9 10/4885CYP2C19 20/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | ATM 4722/4885CYP2C9 271/4885CYP2C19 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.